Log in

NASDAQ:BIOL - BIOLASE Stock Price, Forecast & News

$0.77
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.75
Now: $0.77
$0.82
50-Day Range
$0.57
MA: $0.67
$0.87
52-Week Range
$0.43
Now: $0.77
$2.87
Volume106,131 shs
Average Volume152,064 shs
Market Capitalization$23.93 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Read More…

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.15 million
Book Value$0.54 per share

Profitability

Net Income$-21,520,000.00

Miscellaneous

Employees190
Market Cap$23.93 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.


BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE shares reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) issued its quarterly earnings results on Wednesday, November, 6th. The medical technology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.13. The medical technology company had revenue of $8.65 million for the quarter. BIOLASE had a negative return on equity of 313.64% and a negative net margin of 52.13%. View BIOLASE's Earnings History.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for BIOLASE.

What price target have analysts set for BIOL?

4 brokers have issued 1-year price objectives for BIOLASE's stock. Their forecasts range from $2.00 to $3.00. On average, they expect BIOLASE's stock price to reach $2.50 in the next year. This suggests a possible upside of 223.4% from the stock's current price. View Analyst Price Targets for BIOLASE.

What is the consensus analysts' recommendation for BIOLASE?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

Has BIOLASE been receiving favorable news coverage?

Press coverage about BIOL stock has trended very positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIOLASE earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BIOLASE.

Who are some of BIOLASE's key competitors?

What other stocks do shareholders of BIOLASE own?

Who are BIOLASE's key executives?

BIOLASE's management team includes the folowing people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Archon Capital Management LLC (8.65%) and Perkins Capital Management Inc. (4.26%). Company insiders that own BIOLASE stock include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Institutional Ownership Trends for BIOLASE.

Which institutional investors are buying BIOLASE stock?

BIOL stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Archon Capital Management LLC. Company insiders that have bought BIOLASE stock in the last two years include Garrett Sato, John R Beaver, Jonathan T Md Lord, Larry N Feinberg and Todd Norbe. View Insider Buying and Selling for BIOLASE.

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.77.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $23.93 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

What is BIOLASE's official website?

The official website for BIOLASE is http://www.biolase.com/.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel